The PDE inhibitors market, valued at USD 6.3 billion in 2024, is projected to reach USD 6.7 billion in 2025 and USD 12.7 billion by 2035, representing a CAGR of 6.6% during the forecast period. The success of the marketed PDE drugs has prompted several industry players to undertake initiatives in this area. The fragmented nature of the market is expected to increase the pace of innovation; as more molecules advance to late stage development and eventually get commercialized, we expect the new en...

The global dendritic cell cancer vaccines market is expected to reach $3.2 billion by 2030, growing at an annualized rate of over 20.7%. It is worth noting that in 2016, an estimated 1.7 million new cancer cases were reported in the US alone. Furthermore, as projected by the WHO, the annual incidence of cancer worldwide is expected to rise to 24 million by 2035. As a result, many pharmaceutical companies are working on identifying ways to improve treatment methods, as well as develop new cancer...

The smart wearables market, valued at USD 92.12 billion in 2024, is projected to grow to USD 113.7 billion in 2025 and USD 647.1 billion by 2035, representing a CAGR of 19.0% during the forecast period. Several start-ups, with innovative wearables, have surfaced in the past 6-7 years and have continuously encouraged the use of novel technologies. A sizeable proportion of these companies are focused on gaining foothold in the field of monitoring & diagnosis and wearables offering therapeutic bene...

The global intraocular pressure devices market is expected to reach USD 2.8 billion by 2026, growing at a CAGR of 83.9%. An imbalance in the production and / or drainage of aqueous humor within the eye is known to lead to an increase in intraocular pressure (IOP). Notably, it has been observed that this disease is controlled only in around 50% of patients who have been treated with some form of laser therapy; the effect usually wears off after a period of 5 years. Therefore, in the current scen...

The global HDAC inhibitors market is estimated to grow from USD 1.2 billion in 2024 to reach USD 1.3 billion in 2025 and USD 2.8 billion by 2035, representing a higher CAGR of 7.8% during the forecast period. Currently, HDACs are widely being studied as a promising therapeutic target. HDAC inhibitors can be classified into four main categories based on the structural characteristics of the Zn2+ binding domain. These include hydroxamic acids, cyclic peptides, short-chain fatty acids and benzamide...

The non-insulin therapies market, valued at USD 32.8 billion in 2024, is projected to grow to USD 35.1 billion in 2025 and USD 65.2 billion by 2035, representing a CAGR of 6.4% during the forecast period. Several companies, including both big pharmaceutical players and small to mid-sized companies, are active in this area. Companies engaged in developing anti-diabetic drug classes have actively entered into collaborations with other stakeholders to either acquire / develop / commercialize candid...

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 inhibitor) was the first immune checkpoint inhibitor that was made commercially available in 2011 for treatment of patients suffering from unresectable or metastatic melanoma; it has enjoyed considerable success so far with annual sales of over USD 1 billion. Further, the market, with an opportunistic development pipeline, caters to the participation of various market players (big an...

After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. Notably, a high therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy. With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time...

The dendrimers and polymer drug conjugates market is anticipated to be worth USD 5 billion by 2026. As defined by the National Nanotechnology Initiative, nanotechnology is the branch of science that deals with materials smaller than 100 nanometers. Notably, the discovery of several nanocarriers such as polymers, proteins, micelles, dendrimers, liposomes, emulsions, nanoparticles, each with a unique structure, has provided the drug developers with options to improve the pharmacokinetics and relea...

The PARP inhibitors market is estimated to be worth $8 billion in 2030 and is expected to grow at CAGR of 18% during the forecast period. Cancer is known to be one of the leading causes of death worldwide. According to the International Agency for Research on Cancer (IARC), close to 17 million new cancer cases were reported in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. Therefore, there is a pressing need for more specific and poten...

The global CD19 therapeutics market is estimated to grow from USD 8.5 billion in 2024 to reach USD 9.5 billion in 2025 and USD 26.8 billion by 2035, representing a higher CAGR of 10.9% during the forecast period. The pipeline comprises of products across four major classes of drugs, namely, engineered antibodies, bsAbs, ADCs and CAR-T therapies. The major focus of these novel molecules is hematological cancers, specifically B cell malignancies, with CAR-T therapies leading the table. Post initia...

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes.The resulting antibody has binding affinities for 2 or 3 different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. As of now, only 2 bsAbs, Removab and Blincyt...

The specialty CROs market, valued at USD 3.0 billion in 2024, is projected to grow to USD 3.3 billion in 2025 and USD 7.7 billion by 2035, representing a CAGR of 8.9% during the forecast period. Specialty CROs have emerged as credible players in the market to overcome the shortcomings of full service / traditional CROs. Often, these full-service providers offer a wider portfolio of services but fail to align their efforts to meet the requirements of sponsors, primarily the smaller biotech organi...

The global infusion pumps market size is valued at USD 13.90 billion in 2025 and projected to grow from USD 14.87 billion 2026 to USD 25.39 billion in 2035, representing a CAGR of 6.1% during the forecast period 2026 to 2035. In terms of device type, volumetric pumps currently hold the largest share (30%) due to their high precision, safety, versatility, and broad applications in healthcare (including blood infusion, drug administration, fluid transmission during surgeries, nutrient delivery). A...

The global biotherapeutics market is expected to grow from $4.4 billion to $11.0 billion by 2025 at a CAGR of 9.6%. Biopharmaceuticals is currently one of the fastest growing segments in the biopharmaceutical industry. During the course of our research, we identified 122 such companies that are developing either formulation technologies or novel systems for delivery of large molecule drugs. Further, several start-ups, with innovative technologies, have surfaced in the past decade and have contin...

The NASH drugs market, valued at USD 5.7 billion in 2024, is projected to grow to USD 7.7 billion in 2025 and USD 78.2 billion by 2035, representing a CAGR of 26.1% during the forecast period. Given the rising prevalence of NASH, it has become all the more crucial to understand the pathophysiology of NASH in order to develop therapeutic interventions. Several options are being investigated to identify an efficient treatment regimen for NASH; these include lifestyle modifications, off-label thera...

The global immune checkpoint inhibitors market is likely to be worth $25 billion by 2025. It is worth mentioning that recently, the focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body

The overall anti counterfeit pharmaceutical packaging market is likely to be worth $420 million by 2025, growing at a CAGR of 7%. The major challenge associated with a counterfeit drug is that a non-expert, such as a patient, cannot differentiate between genuine and counterfeit drug without the help of a special instrument or device. These issues have led to the development of many technologies that can be used to detect whether a drug is legitimate or fake. Currently, the market can be categori...

The sustained release ocular drug delivery systems market is likely to be worth $6.95 billion by 2025. Given the intricacy of the anatomy and physiology of the eye, it is quite challenging to deliver an ophthalmic drug effectively to a specific ocular site. Approximately 95% of the drug, in topical eye drops, is lost due to several barriers. Consequently, this widening gap between the demand of novel treatments and supply of drugs/ systems is going to provide a major impetus to the sustained rel...

Targeted cancer therapy is an upcoming area gaining strong foothold in the industry and has already become the focus of a number of pharmaceutical companies. Small molecule protein kinase inhibitors are a type of targeted therapy that involves small molecule drugs administered in the cancer patient for specifically targeting certain proteins, called kinases, involved in the growth of cancer cells. In fact, non-tyrosine kinase inhibitors have gradually gained attention in the last few years. Ther...